Journal of Histochemistry and Cytochemistry Priciples for Free Access to Science
  Search:   
    >> Advanced Search

Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coltrera, M. D.
Right arrow Articles by Gown, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coltrera, M. D.
Right arrow Articles by Gown, A. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

PCNA/cyclin expression and BrdU uptake define different subpopulations in different cell lines

MD Coltrera and AM Gown

Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle 98195.

Monoclonal antibodies (MAb) to a 36 KD protein, proliferating cell nuclear antigen (PCNA/cyclin), have been previously shown to be capable of identifying proliferating cells in vitro as well as in alcohol- fixed, paraffin-embedded tissue specimens. The routine use of these anti-PCNA/cyclin MAb in investigative studies and in diagnostic pathology requires a clearer understanding of the distribution of PCNA/cyclin in the different cell populations found in tissue specimens. We therefore compared the ability of MAb to three nucleus- associated proliferation markers (MAb 19A2 to PCNA/cyclin; Ki-67 to an undefined proliferation-related marker; BU-1 to 5'-bromodeoxyuridine (BrdU) incorporated into DNA) to identify the proliferating cell fraction of various cells in vitro. The cell lines were chosen to represent a spectrum of proliferation rates (high to low) and cell lineage (mesenchymal vs epithelial, non-transformed vs malignant): (a) HeLa and A-431 (two malignant carcinoma cell lines with high proliferation rates); (b) SK-5 (a non-transformed fibroblast cell line with a low proliferation rate); (c) HUVE (a non-transformed human umbilical vein endothelial cell line with a low proliferation rate). Single and double labeling immunofluorescence studies were performed after uniform 1-hr incubations with BrdU. Comparison of the overlapping distributions of detectable PCNA/cyclin expression and BrdU incorporation demonstrated substantial qualitative and quantitative differences between the different cell lines. In two of the four cell lines (HeLa, A-431) the BrdU staining distributions formed inclusive subsets of the PCNA-positive cell populations. In the HUVE cell line the two populations overlapped incompletely. In one cell line, SK-5, the two populations were mutually exclusive. MAb Ki-67 demonstrated a pattern in the SK-5 cell line that was strongly predictive of PCNA positivity, while showing no associated patterns in the other three cell lines. We conclude that PCNA/cyclin expression detected by MAb may define different cell subpopulations in different cell types relative to those incorporating BrdU or expressing the target antigen for Ki-67. This has implications for the clinical study of mixed cell populations using these antibodies.

Volume 39, Issue 1, pp. 23-30, 01/01/1991
Copyright © 1991 by The Histochemical Society


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Toxicol PatholHome page
L. Muskhelishvili, S. K. Wingard, and J. R. Latendresse
Proliferating Cell Nuclear Antigen--A Marker for Ovarian Follicle Counts
Toxicol Pathol, April 1, 2005; 33(3): 365 - 368.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
L. Muskhelishvili, J. R. Latendresse, R. L. Kodell, and E. B. Henderson
Evaluation of Cell Proliferation in Rat Tissues with BrdU, PCNA, Ki-67(MIB-5) Immunohistochemistry and In Situ Hybridization for Histone mRNA
J. Histochem. Cytochem., December 1, 2003; 51(12): 1681 - 1688.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Peng, O. A. Carretero, L. Raij, F. Yang, A. Kapke, and N.-E. Rhaleb
Antifibrotic Effects of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on the Heart and Kidney in Aldosterone-Salt Hypertensive Rats
Hypertension, February 1, 2001; 37(2): 794 - 800.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
P. E. McKeever
Insights About Brain Tumors Gained Through Immunohistochemistry and in Situ Hybridization of Nuclear and Phenotypic Markers
J. Histochem. Cytochem., May 1, 1998; 46(5): 585 - 594.
[Abstract] [Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. Chaux, X. M. Ruan, M. C. Fishbein, M. Sandhu, and J. M. Matloff
INFLUENCE OF VEIN VALVES IN THE DEVELOPMENT OF ARTERIOSCLEROSIS IN VENOARTERIAL GRAFTS IN THE RABBIT
J. Thorac. Cardiovasc. Surg., November 1, 1995; 110(5): 1381 - 1390.
[Abstract] [Full Text]


Home page
ScienceHome page
J. Davis, J. Oberholtzer, F. Burns, and M. Greene
Molecular cloning and characterization of an inner ear-specific structural protein
Science, February 17, 1995; 267(5200): 1031 - 1034.
[Abstract] [PDF]




Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact
The Journal of Histochemistry & Cytochemistry is owned, published, and licensed by The Histochemical Society © 1991